VolitionRx (NYSE-A:VNRX) has issued further equity, a total of 1.95 million shares, as the underwriters of the company’s recent offering exercised an option.
It takes the total raise to US$19.5 million gross, the company said.
Net Proceeds are earmarked for research and continued product development, clinical studies, product commercialization, working capital and other general corporate purposes, including potential strategic acquisitions.